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Abstract: Transglutaminases TG2 and FXIII-A have recently been linked to adipose tissue biology
and obesity, however, human studies for TG family members in adipocytes have not been conducted.
In this study, we investigated the association of TGM family members to acquired weight gain in a rare
set of monozygotic (MZ) twins discordant for body weight, i.e., heavy–lean twin pairs. We report
that F13A1 is the only TGM family member showing significantly altered, higher expression in
adipose tissue of the heavier twin. Our previous work linked adipocyte F13A1 to increased weight,
body fat mass, adipocyte size, and pro-inflammatory pathways. Here, we explored further the link of
F13A1 to adipocyte size in the MZ twins via a previously conducted TWA study that was further
mined for genes that specifically associate to hypertrophic adipocytes. We report that differential
expression of F13A1 (∆Heavy–Lean) associated with 47 genes which were linked via gene enrichment
analysis to immune response, leucocyte and neutrophil activation, as well as cytokine response
and signaling. Our work brings further support to the role of F13A1 in the human adipose tissue
pathology, suggesting a role in the cascade that links hypertrophic adipocytes with inflammation.
Keywords: Factor XIII-A; F131A; obesity; weight gain; adipocyte size; inflammation
1. Introduction
Transglutaminases (protein-glutamine γ-glutamyltransferase, TGase, TG, EC 2.3.2.13) are a
family of enzymes that catalyze a Ca2+- and thiol-dependent posttranslational modification of
glutamine residues [1–4]. These reactions include acyl transfer reaction with primary amines,
glutamine deamination if the second substrate is water, and transamidation, i.e., isopeptide crosslinking,
if the second substrate is a lysine of a protein polypeptide chain. The isopeptide formation between
glutamine and lysine residues, which is by far the most studied reaction of TGs [1–4], stabilizes proteins
and induces formation of protein networks and alterations in substrate protein biochemistry, stiffness,
solubility, and cell adhesive features [2,4–7]. TGs also have cell signaling functions that do not require
crosslinking activity [8].
Int. J. Mol. Sci. 2020, 21, 8289; doi:10.3390/ijms21218289 www.mdpi.com/journal/ijms
Int. J. Mol. Sci. 2020, 21, 8289 2 of 20
The TG family consists of nine gene products: TG1–TG7 and Factor XIII-A [1,2,4] (Genes:
TGM (human), Tgm (mouse)). Transglutaminases TG2 and FXIII-A have been studied widely in the
context of connective tissue hemostasis and differentiation of their resident cell types. While much
focus has been on cartilage and bone [9–15], new research also shows their involvement in adipose
tissue. White adipose tissue (WAT) is a form of connective tissue capable of thermoregulation and
energy storage and it plays a central role in maintenance of balanced energy metabolism [16]. In caloric
excess, WAT expands via preadipocyte proliferation (hyperplasia) and by their differentiation to
lipid storing adipocytes followed by their growth (hypertrophy) [16]. The current understanding is
that adipocyte size is associated with metabolic consequences of obesity in a manner where smaller
adipocyte phenotype predicts healthier outcome, and larger adipocytes are linked to insulin resistance
and other comorbidities of excess weight [17,18]. It is not fully understood why the presence of larger
adipocytes presents a worse metabolic outcome in obesity; however, this may at least not link to
adipocyte mitochondrial dysfunction [19] but rather on hypertrophic adipocyte-mediated initiation of
innate immune reaction [20–22]. In obesity, prolonged inflammation compromises lipid storage and
healthy WAT function, which lead to lipid accumulation to non-metabolic tissues [16,23,24]. This is
linked to the development of insulin resistance and T2D [23].
TG2, which is a ubiquitously expressed TG with a plethora of functions in health and disease,
has been linked to adipogenesis and obesity by us [25] and by others [26]. We demonstrated that
the absence of TG2 in mouse embryonic fibroblasts increased adipogenesis via several pathways,
which included decreased Pref-1 production, canonical Wnt/β-catenin signaling, and increased Akt
phosphorylation [25]. The research group of Szondy showed that Tgm2-deficient mice do not gain more
weight compared to their controls, however they exhibit increased inflammation of adipose tissue.
A recent genome-wide association study by Pietiläinen’s group linked FXIII-A to obesity in
weight discordant monozygotic (MZ) twins, and further studies showed that seven small nucleotide
polymorphisms (SNPs) in the F13A1 gene are associated with body mass index (BMI) [27]. The work by
Kaartinen’s group in turn examined the role and mechanisms of action of FXIII-A in 3T3-L1 adipocytes
and investigated the metabolic phenotype of high-fat diet-fed F13a1-/- mice. We reported that in cell
cultures, the FXIII-A enzyme can act as a switch to modulate insulin signaling from pro-proliferative to
pro-differentiating function via regulating plasma fibronectin accumulation into extracellular fibrils [28].
We also showed that F13a1 deficiency in mice alters the adipose tissue cellularity and increases small
and large adipocytes but decreases macrophage infiltration and improves insulin sensitivity of obese
adipose tissue [29], suggesting that FXIII-A reacts to weight gain and may have an adverse effect on
adipose tissue health. In our most recent work, we examined the association of F13A1 to human obesity
in weight discordant MZ twin pairs, where the association of F13A1 to human obesity was originally
discovered [27]. In this clinical study, we reported that the expression of F13A1 is significantly increased
in the adipose tissue and adipocyte-enriched fraction of the heavier co-twin, and its differential
expression (∆Heavy–Lean) shows a strong, significant linear correlation with increase in weight,
fat mass, and adipocyte volume, and a negative correlation with circulating adiponectin [30]. A further
transcriptome-wide association study (TWAS) between Heavy–Lean ∆F13A1 and changes in full
adipocyte transcriptome between the co-twins identified 182 highly F13A1 correlating transcripts,
for which gene enrichment analysis linked cell stress, inflammation, extracellular matrix remodeling,
and angiogenesis of the adipose tissue.
The aim of this study was first to investigate the expression of the whole TGM family in acquired
excess weight in the MZ twins, and secondly to elucidate details of the links of F13A1 to pathways
associated with adipocyte size that may be relevant to metabolism. We report that F13A1 is the
only TGM family gene transcript that is significantly linked to acquired weight gain, showing an
increase in the heavier twin. F13A1 associated with 47 gene transcripts that also showed a link to large
adipocyte size, which mostly represented genes of neutrophil attraction, inflammasome, and secretion
of pro-inflammatory cytokines. Our study brings further evidence to the relevance of FXIII-A/F13A1 in
adipose tissue health.
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2. Results
Our first aim was to examine potential links of TGM family members to excess acquired weight
in the 12 weight discordant MZ twins. The significant weight and adipocity discordance of the
twins are presented in Table 1. Differential (∆Heavy–Lean twin) gene expression in adipose tissue
and adipocyte-enriched fraction is reflective of cellular changes in the tissue upon its expansion
during weight gain. As presented in Figure 1A,B, F13A1 is the only TGM family gene that reacts to
excess weight in a significant manner and shows increased expression in both adipose tissue and
adipocyte-enriched fraction of the heavier twin [30].
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Figure 1. Gene expression of transglutaminase family genes and association of F13A1 mRNA expression
in acquired excess weight. Increase in tr nsglutaminase family (TGM) members in excess weight
repres nted by expression difference (∆) betwe n heavy and lea monozygotic ( Z) weight discordant
twins (n = 12 twin pairs). (A) Differential expression in adipoc te-enriched fraction. (B) Differential
expression in adipose tissue. Analysis of variance (ANOVA) with Bonferroni post-test shows that
F13A1 is the sole TGM family member that reacts to acquired excess weight in both pre arations.
No significant changes were observed in other TGM family members. NS, not significant.
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Table 1. Clinical characteristics of the twin pairs (n = 12) used in this study to obtain transcriptomics
data from adipose tissue and adipocyte-enriched fraction. Student’s T-test was used to calculate the
differences between the twin pairs, and Wilcoxon Signed rank’s test to determine the p-values.
Clinical and Adipocity Parameters Heavier Co-twin Leaner Co-twin p-Value
Height (cm) 169.3 ± 2.89 169.2 ± 3.0 0.7530
Weight (kg) 83.8 ± 4.6 67.0 ± 4.1 0.0022
BMI (kg/m2) 29.0 ± 0.85 23.2 ± 0.7 0.0022
Body fat (%) 41.9 ± 2.0 32.8 ±1.8 0.0029
Body fat (kg) 34.7 ± 2.3 22.0 ± 1.9 0.0022
Fat-free mass (kg) 46.6 ± 3.7 42.8 ± 2.9 0.0029
Subcutaneous fat (dm3) 5762.4 ± 450.6 3303.6 ± 275.4 0.0022
Intra-abdominal fat (dm3) 1109.8 ± 186.4 502.2 ± 91.2 0.0037
Liver fat (%) 2.4 ± 0.74 0.60 ± 0.06 0.0076
Triglycerides (mmol/L) 1.14 ± 0.07 0.96 ± 0.11 0.1823
fP-Leptin (pg/mL) 34,229.0 ± 5931.3 18,331.8 ± 4412.6 0.0037
fP-Adiponectin (ng/mL) 2844.0 ± 382.1 3520.1 ± 380.1 0.0186
Adipocyte diameter (mm) 87.9 ± 2.82 76.6 ± 2.77 0.0022
Adipocyte number 8.8e + 13 ± 5.7e + 12 8.5e + 13 ± 8.2e + 12 0.4328
BMI: body mass index, fP: fasting plasma. Data are presented as mean ± SEM.
Our previous work linked increase in F13A1 expression to increase in adipocyte size/volume [30].
This, with previous mouse data, suggests that F13A1 may be increasingly produced by larger adipocytes
or may regulate the cell size. In the same study, we identified 182 F13A1- and weight-associated
genes which showed significant (p < 0.05) and strong Pearson correlation (r > 0.7) for Heavy–Lean
∆F13A1 [30]. Gene enrichment analysis showed that the 182 genes linked to cell stress, inflammation,
tissue remodeling, hemostasis, and angiogenesis [30]. To further examine the link of F13A1 to adipocyte
size, we applied the following strategy (Figure 2). First, the pool of 182 genes was further screened
for genes that also showed correlation to Heavy–Lean ∆Adipocyte Diameter in the 12 MZ twin pairs.
This resulted in a total of 283 genes from which 42 were found as shared with the original 182 gene
set. Second, we screened the set for adipocyte size correlating (positive and negative) genes that were
identified from 15 MZ twins, some of which were shared with this study [17]. This resulted in no
additional genes (Supplemental Tables S1 and S2). Third, we screened 14 reported ‘large adipocyte
genes’ from a study where adipocytes, isolated from human SAT, were separated via 70 µm mesh into
small (57.8 ± 0.23 µm) and large (95 ± 0.38 µm) adipocytes, followed by mRNA expression analysis
and identification of genes that were expressed more than four-fold in large adipocytes versus small
ones [18,31] (Supplemental Table S3). From this set, three additional F13A1- and weight-correlated
genes were identified (SELE, IL8, and LPCAT1). Fourth, we searched the literature for genes that have
been published to regulate adipocyte size. A literature search (‘adipocyte size’ and ‘regulation’ and
‘gene’) resulted in 835 papers, from which 17 reported on genes with strong links to regulation of
adipocyte size (associations were not included) (Supplemental Table S4). Only one out of these genes
was found in the set of 182 genes (REPIN1). Thus, a total of 383 ‘adipocyte size’ genes were screened,
which resulted in a final set of 47 gene transcripts that showed significant correlation to ∆F13A1 and
were differentially expressed in the Heavy vs. Lean twin. Classical regulators of adipogenesis and
lipid storage, PPARG, CEBPA, CEBPB, and PLIN1, did not show correlation. The set of 47 genes are
listed in Table 2. From this set, 12 genes showed strong negative correlation with ∆Weight-, ∆F13A1-,
and ∆Adipocyte Diameter. The remaining 35 genes were positive correlators.
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Figure 2. Transcriptome-wide association study (TWAS) strategy to investigate the association of
F13A1 with acquired excess weight and adipocyte size in weight-discordant monozygotic twins.
To examine what weight gain and adipocyte size-associated pathways F13A1 is linked to, we performed
a transcriptome-wide association study (TWAS) of differentially expressed and correlated genes
(Heavy–Lean ∆F13A1 vs. Heavy–Lean ∆transcriptome). The initial screen identified 182 genes whose
differential expression showed significant linear correlation with F13A1 (r2 > 0.5 and p < 0.05) and
significant differential expression between the Heavy and Lean co-twins (p < 0.05) [32]. This set was
screened for previously published adipocyte size correlating (positive and negative) genes in the MZ
twins, some of which were shared with this study. This resulted in no additional genes. The set was
then screened for 14 reported ‘large adipocyte genes’ and 17 genes from the literature that have been
published to regulate adipocyte size (PubMed search (‘adipocyte size’ and ‘regulation’ and ‘gene’)).
All screened genes are listed in Supplemental Tables S1–S4. The resulti g final set f 47 genes that
correlated with F13A1, adipocyte diam ter, and wer differentially expressed in th c -twin pairs are
listed in Table 2.
Table 2. List of 47 genes showing strong and significant correlation Heavy–Lean ∆F13A1, ∆Adipocyte
Diameter, and significantly altered expression between the 12 MZ co-twins. Genes are ranked based on
smallest p-value.
Positive Correlation
Gene Symbol Gene ID Gene Name Pearson (r) p-Value
CPVL ENSG00000106066 Carboxypeptidase, vitellogenic-like 0.946 0.00000097
PYCARD ENSG00000103490 PYD and CARD domain containing 0.941 0.00000167
CTSS ENSG00000163131 Cathepsin S 0.902 0.00002544
ITGAM ENSG00000169896 Integrin subunit alpha M 0.885 0.00005774
DCLK1 ENSG00000133083 Doublecortin-like kinase 1 0.867 0.00012405
CYBB ENSG00000165168 Cytochrome b-245 beta chain 0.856 0.00018955
SRGN ENSG00000122862 Serglycin 0.842 0.0003081
TM4SF1 ENSG00000169908 Transmembrane 4 L six family member 18 0.834 0.00039092
PDE4B ENSG00000184588 Phosphodiesterase 4B 0.834 0.00039317
TFPI ENSG00000003436 Tissue factor pathway inhibitor 0.83 0.00044582
ANXA4 ENSG00000196975 Annexin A4 0.827 0.00049387
IL8 ENSG00000169429 Interleukin 8 0.806 0.00087858
VCAN ENSG00000038427 Versican 0.806 0.00088439
BCL2A1 ENSG00000140379 BCL2-related protein A1 0.802 0.00097386
LCP1 ENSG00000136167 Lymphocyte cytosolic protein 1/Plastin-2 0.802 0.00097956
RECK ENSG00000122707 Reversion inducing cysteine-rich protein withkazal motifs 0.799 0.00105162
ABI3BP ENSG00000154175 ABI family member 3 binding protein 0.795 0.00115971
IL1B ENSG00000125538 Interleukin 1 beta 0.786 0.00145102
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Table 2. Cont.
Positive Correlation
Gene Symbol Gene ID Gene Name Pearson (r) p-Value
SAMSN1 ENSG00000155307 SAM domain, SH3 domain, and nuclear localizationsignals 1 0.78 0.00165797
RGS1 ENSG00000090104 Regulator of G protein signaling 1 0.775 0.00186205
CCDC109B ENSG00000005059 Mitochondrial calcium uniporter dominant negativebeta subunit 0.774 0.0018858
NCEH1 ENSG00000144959 Neutral cholesterol ester hydrolase 1 0.766 0.0022702
ARPC5 ENSG00000162704 Actin-related protein 2/3 complex subunit 5 0.764 0.00235294
LYZ ENSG00000090382 Lysozyme 0.762 0.00247521
MAPK1 ENSG00000100030 Mitogen-activated protein kinase 1 0.743 0.00359262
HLA-DRA ENSG00000204287 Major histocompatibility complex, class II, DR alpha 0.743 0.00361775
ARHGAP18 ENSG00000146376 Rho GTPase activating protein 18 0.743 0.00364017
TNFSF13B ENSG00000102524 TNF superfamily member 13b/B cell activation factor 0.739 0.00393293
WIPF1 ENSG00000115935 WAS/WASL interacting protein family, member 1 0.728 0.00481724
CNKSR3 ENSG00000153721 CNKSR family member 3 0.725 0.00503039
MGP ENSG00000111341 Matrix Gla protein 0.72 0.00555039
EVI2A ENSG00000126860 Ecotropic viral integration site 2A 0.717 0.00579394
NPTN ENSG00000156642 Neuroplastin 0.715 0.00596749
SELE ENSG00000007908 Selectin-E 0.778 0.00174649
LPCAT1 ENSG00000153395 Lysophosphatidylcholine acyltransferase 1 0.732 0.00445358
Negative Correlation
Gene Symbol Gene ID Gene Name Pearson (r) p-Value
SCRN2 ENSG00000141295 Secernin 2 –0.876 0.000086
PTPRF ENSG00000142949 Protein tyrosine phosphatase receptor type F –0.84 0.00033
EMC3 ENSG00000125037 ER membrane protein complex subunit 3 –0.816 0.000673
ABCD1 ENSG00000101986 ATP binding cassette subfamily D member 1 –0.793 0.001229
PLA2G16 ENSG00000176485 Phospholipase A and acyltransferase 3 –0.784 0.001527
NFRKB ENSG00000170322 Nuclear factor related to kappaB binding protein –0.74 0.00386
HEPACAM ENSG00000165478 Hepatic and glial cell adhesion molecule –0.734 0.00426
RBP1 ENSG00000114115 Retinol binding protein 1, cellular –0.725 0.00501
STAT5A ENSG00000126561 Signal transducer and activator of transcription 5A –0.72 0.00556
TUSC5 ENSG00000184811 Tumor suppressor candidate 5/Trafficking regulatorof GLUT4 –0.717 0.005843
COX5A ENSG00000178741 Cytochrome c oxidase subunit Va –0.712 0.006346
REPIN1 ENSG00000214022 Replication initiator 1 –0.772 0.001987
Gene enrichment analysis for the 47 genes, with GOnet and Panther gene ontology tools, resulted
in a total of 61 GOterms for Biological Process (BP), 13 Cellular Component (CC), and no terms
for Molecular Functions. Figure 3 shows a selection [28] of the most significant, over-represented
Biological Process GOterms and all 13 Cellular Component terms. The full list of GOterms is listed in
Supplemental Tables S5 and S6. Further cluster analysis (Figure 4) for the GOterms using the GOnet
tool revealed three clear functional clusters related to immune response, inflammation, and cytokine
response and signaling. A detailed examination of each of the clusters revealed central GOterms,
suggesting inflammatory response to external factors via neutrophil and leucocyte activation as well as
cytokine secretion (Figures 5–7). Each of the Biological Process and Cellular Component terms and
some relevant genes are discussed below in more detail.
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differential expression correlated with F13A1, adipocyte diameter, and showed significantly altered
expression between heavy and lean c -twins. Gen ontology analysis was done using GOnet and
confirmed with Panther. A total of 61 GOterms were found for Biological Process, and 28 highly
relevant are represented here. All 13 Cellular Component terms are shown. No terms for Molecular
Functions arose in the search. Signific nce of the terms is represented as –log10 (p-value) and number
of genes in each GOterm is indicated with the bar. Full set of the GOterms with p-values, as well as
false discovery rate adjusted p-values and list of genes can be found in Supplemental Tables S5 and S6.
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3. Discussion
Adipose tissue expansion through hypertrophy, where large adipocytes predominate in the
expanding tissue, correlates with adipose tissue low-grade systemic inflammation and worse
metabolic consequences of obesity [33–36]. The mechanisms and pathways that precede and follow
the hypertrophic expansion and inflammation are numerous. Accumulating data points to sequela
that involves free fatty acid (FFA)-mediated initiation of adipocyte hypertrophy, which is followed
by initiation of innate immune response by the hypertrophic adipocytes [34]. Previous studies
have linked two TGM family members, TGM2 and F13A1, to adipose tissue biology and
inflammation [25,26,28–30,37–39]. In this study, we have investigated the differential expression
of the whole TGM family in adipose tissue of MZ twins that are discordant in weight (Heavy–Lean twin
pairs). The MZ twins are a unique model of acquired weight gain where background involving genetic,
age, sex, and early environmental influences can be controlled. The twins’ adipocity parameters and
metabolism are well characterized and include adipocyte morphology, mitochondrial, fibronolytic
and coagulatory, and inflammatory status [40–47]. We report that F13A1 is the sole TGM family
member that shows significantly altered, and in this case increased, expression in the heavier twin.
Despite robust data from mouse studies linking TG2 to adipose tissue function in obesity [25,26],
TGM2 showed no altered expression between the Heavy–Lean co-twins. Further studies in larger
cohorts of more severely obese individuals could shed more light into the role of TG2 in human adipose
tissue pathology.
The presence of large versus small adipocytes in adipose tissue in obesity has been associated
with worse metabolic outcome [18]. Our previous work linked increase in F13A1 in adipose tissue to
increased adipocyte size [30]. The aim of this current study was to further examine through which
pathways F13A1 associates to large adipocytes. This was done by screening the pool of the previously
identified 182 F13A1- and weight-correlating genes [30] in the adipocyte-enriched fraction for: (1) genes
that have been reported to associate positively or negatively to adipocyte size [17], and (2) genes that
are expressed significantly more in larger adipocytes or demonstrated in the literature to regulate
adipocyte size [18,31]. Here, we demonstrate tight association of F13A1 to 47 ‘adipocyte size’ genes that
via gene enrichment analysis linked to Biological Processes involving response to external stimulus,
secretion, exocytosis, vesicle-mediated transport, cell surface receptor signaling, neutrophil activation,
and response to interleukin 1. The GOterms for Cellular Components suggested association of F13A1
in lysosome, secretory vesicles, plasma membrane rafts, and extracellular space. Network and cluster
analysis of the GOterms link these to immune response/inflammation and cytokine response (Figure 4),
which jointly suggest that F13A1 may be involved in pro-inflammatory response from large adipocytes.
In our previous study, we discussed several genes that are also among the current 47 genes and
they were associated with adipocyte oxidative stress, extracellular matrix (ECM) organization and
remodeling, angiogenesis, and macrophages [30]. Associations to all the above processes suggests that
F13A1 may be involved throughout in molecular events of the tissue expansion.
The adipocyte-enriched fraction used in this study was prepared from SAT biopsies by a method
involving collagenase digestion followed by collecting of the released, buoyant adipocytes. This method
is considered to separate adipocytes from the stromal vascular fraction that contain pre-adipocytes,
mesenchymal stem cells, endothelial and vascular smooth muscle cells, and immune cells [48], however,
other cell types do co-purify and contribute to the transcripts observed. Thus, the preparation
enriches adipocytes, but is not void of other cell types. It has become apparent that pure adipocyte
preparations require flow cytometry sorting and is more difficult than previously considered [49].
The other cell types have likely co-purified and may include macrophages whose marker ITGAM
(Integrin αM; CD11b) is present also in this final set of 47 genes. The preparation also likely includes
endothelial cells, which as suggested by the expression of genes like SELE (Selectin E) [30], is a product
of cytokine-stimulated endothelial cells and mediates endothelial cell adhesion to leucocytes [50].
Macrophages and endothelial cells also both produce FXIII-A enzyme [3,51–59]. Our major future aims
include detailing the cell types that are responsible for F13A1/F13a1 production at different phases
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of adipose tissue expansion, which is critical to understanding where in the inflammatory sequela
F13A1/F13a1 may be involved.
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Figure 5. F13A1 expression in adipocyte-enriched fraction associates with neutrophil activation and early
immune response. (A) Map of GOterm nodes representing Biological Processes involved in immune
response. Node clusters for neutrophil activation, secretion, and regulation of immune response are
evident. Gene lists for representative nodes are shown. (B) Linear correlation of ∆F13A1 (Heavy–Lean
twin) with differential expression ∆gene (Heavy–Lean twin) of selected genes from GOterms.
F13A1 levels incr se in adipocyte-enriched fraction together with PYCARD (an inflammasome
and caspase-1 activator), IL1B (interleuk n 1b) (early pro-inflammat y cytokine), and HLA-DRA
(HLA class II histoco patibility antigen presenting factor, and TNFSF13B (TNF Superfamily Member
13b and B-cell activating factor)).
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Of the 47 gene transcripts that correlate with weight, F13A1, and adipocyte size, we have discussed
four in our previous study (CYBB, CTSS, ITMG, and VCAN) [30]. Below, we will focus mostly on the
new ones identified here. The most numerous GOterms for Biological Processes were associated with
neutrophil and leucocyte activation (Figure 5). One of the highest F13A1 correlating genes in this set
was PYCARD (r2 = 0.89) (Figure 5B), which encodes for ASC (apoptosis-associated speck-like protein
containing a CARD). PYCARD/ASC is made up by macrophages, where it activates inflammasome via
acting as an adaptor protein between Nlrp3 and caspase-1 [60]. Caspase-1 is critical for proteolytic
activation and secretion of pro-inflammatory cytokines IL1β and IL-18 [61,62]. The presence of FFAs
in adipose tissue can induce activation of inflammasome [61] and its essential role in metabolic
disturbances has become clear [61,63,64]. A very recent work demonstrated that the absence of these
three critical inflammasome components, Nlrp3, ASC, and caspase-1, in mice protects mice from
HFD-induced obesity, insulin resistance, and adipocyte hypertrophy [64]. The Heavy–Lean increase in
∆IL1B also shows strong linear correlation to ∆F13A1 (r2 = 0.62) (Figure 5B). IL1β is one of the major
pro-inflammatory cytokines whose role in metabolic dysfunction is well documented [65].Int. J. Mol. Sci. 2018, 19, x FOR PEER REVIEW  12 of 22 
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Figure 6. F13A1 expression in adipocyte-enriched fraction associates with cytokine-mediated signaling
pathways. (A) Map of GOterm nodes representing Biological Processes involved in responding to
external stimuli. Gene lists for representative nodes are shown. (B) Linear correlation of ∆F13A1
(Heavy–Lean twin) with differential expression ∆gene (Heavy–Lean twin) of selected genes from
GOterms. F13A1 levels in adipocyte-enriched fraction negatively correlate with PTPRF, a positive
inhibitor of insulin signaling, and to STAT5A, a promoter of adipocyte differentiation.
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Figure 7. F13A1 expression in adipocyte-enriched fraction associates with immune response to
external factors and stimulus. (A) Map of GOterm nodes representing Biological Processes involved in
responding to external stimuli. Gene lists for representative nodes are shown. (B) Linear correlation
of ∆F13A1 (Heavy–Lean twin) with differential expression ∆gene (Heavy–Lean twin) of selected
genes from GOterms. F13A1 levels in adipocyte-enriched fraction correlate negatively with PLA2G16
(phospholipase A2), a lipolytic enzyme, and positively with expression of MAPK1.
Neutrophils are the first responders of acute inflammatory reaction and are the first cells to be
recruited to the site of inflammation [66–69]. They are the most populous but short-lived cell type
in early inflammation and are capable of producing large quantities of cytokines and chemokines,
including TNF-α, IL-1β, and IL-8, which can initiate the second wave of immune cells, such as
infiltration of macrophages and lymphocytes [66–69]. The role of neutrophils in adipose tissue
inflammation has also become apparent [33,70,71]. The links of F13A1 to both neutrophil and
leucocyte activation (Figure 5) supports a role in early inflammation as well as perpetuation of
the pro-inflammatory milieu. The genes contributing to GOterms that link F13A1 to neutrophil
activation are, among others, CYBB (NADP oxidase) (Nox2), which is made by neutrophils and
macrophages and responsible for generation of reactive oxygen species and oxidative stress, which
in turn can activate neutrophils and neutrophil extracellular trap formation [72]. In adipose tissue,
CYBB/Nox2 contributes to adipose tissue inflammation and development of insulin resistance [73].
Int. J. Mol. Sci. 2020, 21, 8289 12 of 20
The presence of TNFSF13B (TNF Superfamily Member 13b) (also known as BAFF) in the set of
47 weight and F13A1 correlating genes also supports neutrophil links (Figure 5B). TNFSF13B/BAFF is a
neutrophil-derived cytokine that supports B lymphocyte survival. B lymphocytes can tune adipose
tissue inflammation via secreting cytokines and immunoglobulins, and they contribute to metabolic
failure of adipose tissue [63,74,75]. BAFF is also produced by adipocytes [76]. The role of F13A1 in
inflammation in many tissues is supported by vast literature and it is expressed by macrophages
and dendritic cells [51,52,77–82]. The mechanisms by which FXIII-A contributes to inflammation
involve its fibrin-stabilizing function [83,84] and monocyte/macrophage adhesion [79,85]. It may also
crosslink other substrates such as plasma fibronectin [28,29]. It is not known if F13A1 is produced by
neutrophils themselves.
Cluster analysis of GOterms also revealed that F13A1 links to cytokine-mediated signaling
pathways (Figure 6). Here, we demonstrate two indicators that show that F13A1 is also negatively
associated with important insulin modifiers, which is apparent from its negative correlation to
PTPRF and STAT5A. The ∆F13A1/∆PTPRF linear regression graph in Figure 6B shows that the high
increase in F13A1 correlated with a smaller increase in PTPRF. PTPRF encodes for Protein Tyrosine
Phosphatase Receptor Type F (also known as LAR), which inhibits the insulin receptor activation [86,87].
PTPRF/LAR knockdown in adipocytes increases adipogenesis [88] and in mice, disturbances in glucose
homeostasis [89]. This data interestingly links high F13A1 to promotion to insulin signaling, which we
demonstrated in 3T3-L1 adipocytes [28]; however, in mice, the F13A1 absence improves insulin
sensitivity [29]. Also, negative association to STAT5A (Figure 6B) (Signal Transducer and Activator
of Transcription 5A), a known promoter of adipogenesis and adipocyte differentiation, supports our
previous cell culture results, where FXIII-A was required for pre-adipocyte proliferation but was
rapidly downregulated during adipogenesis [28]. The link to large adipocytes suggests that it is also
made later during hypertrophy, however this could also mean that large adipocytes induce F13A1
in other adipose tissue cells. Interestingly, recent advances in understanding the phenotypes and
functionality of large, hypertrophic adipocytes in adipose tissue in obesity has shown that they likely
function as antigen-presenting cells to active innate immunity/immune cells via MHCII and play
an important role in the initiation of adipose tissue inflammation [20,90]. Mature adipocytes have
also been demonstrated to express leucocyte chemo-attractants that via direct adipocyte–leucocyte
interaction stimulate T-cell proliferation [91]. The correlation of F13A1 to HLA-DRA (Figure 5B),
an HLA class II histocompatibility complex component, found on the surface of antigen presenting
cells, could suggest a link to large adipocytes specialized to initiation of inflammation.
The stimuli initiating F13A1 production, cell types producing it, and cellular
location/externalization and activation in adipose tissue are major questions arising from this study.
Here, the increase of F13A1 is linked to GOterms for cellular response to external stimuli and response
to lipopolysaccharide (LPS), supporting the idea that F13A1 could be induced by those factors that
initiate the inflammatory reaction. The stimuli that can initiate adipose tissue inflammation are complex
and numerous [33,34] and include fibrosis and alterations in extracellular matrix components and
stiffness [83,92–96], apoptosis and necrosis of hypertrophic adipocytes [97], hypoxia from defective
angiogenesis [24,98], free fatty acids (lipotoxicity) [21], and exogenous, as well as gut microbiota-derived
LPS [36]. The GOterms for this cluster of Biological Processes are presented in Figure 7, and there
are two genes of particular interest PLA2G16 and MAPK1.PLA2G16—phospholipase 2A—a lipolytic
enzyme made in hypertrophic adipocytes that produces FFAs and induces hyperlipidemia [99,100].
Coregulation between PLA2G16 and F13A1 could thus imply a link to FFAs. Positive association with
MAPK1 (Figure 6B) is also worthy of mention as we demonstrated that in osteoblasts, extracellular
collagen type I, also produced by adipocytes, is a major regulator of FXIII-A expression and
externalization [15]. MAPK1 is also needed for lipolysis in rat and mouse adipocytes [101,102].
Our original screen contained a set of regulatory genes demonstrated to modulate adipocyte
size. From the final set of genes, 46 of the 47 were large adipocyte-associated genes and only one,
REPIN1, was a gene that has been demonstrated to regulate adipocyte size and whole-body insulin
Int. J. Mol. Sci. 2020, 21, 8289 13 of 20
sensitivity [103]. The association between F13A1 and REPIN1 is negative (r =−0.77; r2 = 0.70; p = 0.0002),
i.e., higher ∆REPIN1 levels link to lower ∆F13A1. This and the positive association of ∆F13A1 to
∆Adipocyte Diameter and ∆Adipocyte Volume [30] strongly suggests that majority of F13A1 is a result
of adipocyte hypertrophy-induced events in weight gain, rather than it being a gene that influences the
adipocyte size. Detailed weight gain studies in mice can address when F13a1 transcription and protein
production is initiated, when and how it is activated during adipose tissue expansion, and what are
the consequences of its absence or its overexpression to adipocytes and adipose tissue inflammatory
cells and processes. These studies are ongoing in our laboratory.
In conclusion, our study brings further evidence to the involvement of F13A1 in the pathological
response of adipose tissue to expansion in weight gain in humans. The concepts revealed in our study
suggest novel pathways linked to F13A1 and inflammation providing many new hypotheses to be
explored that will hopefully show if FXIII-A could be a target to control inflammation of adipose tissue.
4. Materials and Methods
4.1. Weight-Discordant MZ Twins
This study involved 12 rare, healthy MZ twin pairs discordant for weight (intra-pair difference
in acquired excess weight ∆BMI (body mass index) ≥ 3 kg/m2 (males n = 2, females n = 10,
aged 27, 7 ± 1.4 years)) which were identified from two population-based twin cohorts, FinnTwin16
(n = 2839 pairs) and FinnTwin12 (n = 2578 pairs) [104]. A detailed description of the twin material has
been published previously [45,105]. The twins were healthy and were not on any regular medication,
excluding contraceptives. Table 1 describes the clinical characteristics of the 12 twin pairs regarding
weight and adipocity. This data table has been also presented in Reference [30]. All participants have
given a written informed consent. The study design was approved by the Ethical Committee of the
Helsinki University Central Hospital.
4.2. Adipose Tissue Biopsies, Adipocyte and Tissue Preparations, and RNA Extraction
Abdominal subcutaneous adipose tissue (SAT) biopsies were obtained surgically under
the umbilicus under local anesthesia. Specimens were flash frozen in −80 ◦C liquid nitrogen.
Adipocyte-enriched fraction was prepared by a previously reported protocol which involved adipose
tissue digestion in 2% collagenase dissolved in DMEM/F-12 with supplements and 2% bovine
serum albumin [17]. This was followed by adipocyte mRNA extraction using RNeasy Lipid Tissue
Mini Kit (Qiagen, Nordic, Solletuna, Sweden) with a DNase I (Qiagen) digestion according to the
manufacturer’s instructions.
4.3. Adipocyte Morphology
Fresh SAT biopsy specimens were digested with 2% collagenase in DMEM/F12 with
supplements [17] and 2% bovine serum albumin (as above) and were used for measurement and
calculation of adipocyte size in all 12 discordant twin pairs, as before [17]. After collagenase treatment,
the digests were washed and maintained in the above medium and images of live adipocytes were
taken with a light microscope (Zeiss, Axioplan2) using 50×magnification. A minimum of 200 cells were
measured for diameter using an image processing and analysis software ImageJ (ImageJ 1.42q/Java 1.
6.0_10 32-bit), as previously described [17].
4.4. Affymetrix Transcriptomics
A total of 500 ng of RNA from adipocyte-enriched fraction, isolated as described above, was used for
gene expression analysis on an Affymetrix U133 Plus 2.0 array (Thermo Fischer, Santa Clara, CA, USA)
according to the manufacturer’s instructions and validated as described previously [45]. Hybridization,
staining, and washing were performed using the Affymetrics Fluidics Station 450 and Hybridization
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oven 640 under standard conditions. Expression data was pre-processed with BioConductor software
(open source, www.bioconductor.org) and the GC-RMA algorithm [106].
4.5. Transcriptome-Wide Association Study, Statistics, and Bioinformatics
Intra-pair values (∆Heavy–Lean) for twins’ transcriptome (differential gene expression, ∆) were
calculated and screened for correlation to intra-pair ∆F13A1 expression in adipocyte-enriched fraction
using R Statistical Software (https://www.r-project.org/) [107]. Significance within the TGM family
(TGM1-7 and F13A1) expression in twin pairs was calculated via analysis of variance (ANOVA) with
Bonferroni post-test using Prism GraphPad software (release 8.0, San Diego, CA, USA). p-Values < 0.05
were considered significant. Pearson (r) correlation and r2 parameters were obtained for ∆F13A1 and
∆Adipocyte Diameter, and those with r2 > 0.5 and associated p-values < 0.05 were considered for
further screening. Normal distribution of F13A1 mRNA expression values and adipocyte diameter
values were assessed as before [30]. Significance of differential gene expression between the co-twins
was tested with a paired T-test and associated p-values < 0.05 were considered significant. Further linear
regression analysis was performed for selected genes with significant associations to ∆F13A1 with
Prism GraphPad software (release 8.0, San Diego, CA, USA). Here, p-values were considered significant
as follows: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. Gene Ontology enrichment analysis and
GOterm cluster analysis for over-represented genes from transcriptome screening was performed using
Panther, GOnet, and Gorilla online tools. Significance for GOterms is represented in False Discovery
Rate (FDR) adjusted p-values.
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